Global Hemophilia Market-Industry Analysis and forecast 2019 – 2027: By Type, Treatment, Replacement therapy, and Region.

Global Hemophilia Market-Industry Analysis and forecast 2019 – 2027: By Type, Treatment, Replacement therapy, and Region.

Market Scenario

Global Hemophilia Market size was valued at US$ XX Bn. in 2019 and the total revenue is expected to grow at 6.2% from 2019 to 2027, reaching nearly US$ 16.2 Bn.   Global Hemophilia Market   Hemophilia is a rare disorder that is difficult to diagnose and to manage. It has an estimated frequency of about one in 10,000 births. Hemophilia treatment includes medication treatment to improve blood clotting. Hemophilia symptoms, hemophilia genotype, hemophilia life expectancy, hemophilia diagnosis hemophilia genetics, are a few of the concerned issues of the end-users in the hemophilia market. As per the NHF (National Hemophilia Foundation), the U.S, two main forms of hemophilia arise much more frequently in men than in women. Globally, Hemophilia-A is the most dominant type of condition with the occurrence rate of 1 in 4000 to 1 in 5000 men who are born with this disorder. While the occurrence rate of Hemophilia-B is nearly 1 in 20,000 newborn males. Upgradation of new therapeutics and simultaneously working and continuous development and growth of the current treatment options have presented great and novel opportunities to the hemophilia market globally. Likewise, the global hemophilia market dynamics are thoroughly studied and explained in the MMR report, which helps to understand emerging market trends, drivers, restraints, opportunities, and challenges at the global and regional level for the hemophilia market. The MMR report also covers the segments in the hemophilia market such as type, treatment, and replacement therapy. Based on treatment, the prophylaxis segment dominated the hemophilia market, with a market size of US$ XX Mn. in 2019 and to reach US$ XX Mn. by 2027, with a CAGR of XX.67%. Long-lasting prophylaxis treatment is considered a standard of care to prevent joint bleeding and chronic arthropathy in patients with severe hemophilia. By type, Hemophilia-A is expected to continue to hold the largest XX% share in the hemophilia market owing to a growing prevalence of hemophilia. Such as BioMarin Company is involved in emerging Valoctocogene Roxaparvovec “BMN-270” for hemophilia-A type patients and is currently under clinical trials. North America accounted for the largest hemophilia market share in 2019, with a market value of US$ XX.10 Mn; the regional market is expected to register a CAGR of XX.43% during 2019-2027. This is because of well-recognized clinical infrastructure and growing knowledge between citizens about the different treatments accessible to treat hemophilia disease. However, the Asia Pacific and Latin America regions are projected to experience substantial development in the future thanks to the growing knowledge about technologically developed products. Currently, various companies in the hemophilia market are focusing on organic growth strategies such as product approvals, product launches, and other patents and events. In 2019, Roche Company announced Emicizumab i.e. Hemlibra, which was accepted in India for Hemophilia-A with the reason VIII inhibitors. It was specified as a treatment of prophylactic preventive which reduces or prevents the frequency of the bleeding periods. The objective of the report is to present a comprehensive analysis of the Global Hemophilia Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Hemophilia Market dynamics, structure by analyzing the market segments and projects the Global Hemophilia Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Hemophilia Market make the report investor’s guide.

Scope of the Global Hemophilia Market

Global Hemophilia Market, By Type

• Hemophilia-A • Hemophilia-B • Hemophilia-C • Others

Global Hemophilia Market, By Treatment

• On-demand • Prophylaxis

Global Hemophilia Market, By Replacement therapy

• ITI therapy • Gene therapy

Global Hemophilia Market, By Region

• Asia Pacific  India  China  Japan  South Korea  Australia  Indonesia  Malaysia  Vietnam  Rest of Asia • North America  U.S.  Canada • Europe  U.K  Germany  France  Russia  Spain  Italy  Sweden • South America  Mexico  Brazil  Rest of South America • Middle East & Africa  GCC  South Africa  Rest of MEA

Key players operating in the Global Hemophilia Market

• F.Hoffmann-La Roche Ltd • Octapharma • CSL Behring • Kedrion • Sanofi • Bayer AG • Baxter • Swedish Orphan Biovitrum AB • Grifols International S.A • Shire • Pfizer Inc • Novo Nordisk A/S • Chugai Pharmaceutical Co. (Roche) • BioMarin Pharmaceutical, Inc

Table of Contents

Global Hemophilia Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Hemophilia Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Hemophilia Market Analysis and Forecast 6.1. Hemophilia Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Hemophilia Market Analysis and Forecast, By Replacement therapy 7.1. Introduction and Definition 7.2. Key Findings 7.3. Hemophilia Market Value Share Analysis, By Replacement therapy 7.4. Hemophilia Market Size (US$ Bn) Forecast, By Replacement therapy 7.5. Hemophilia Market Analysis, By Replacement therapy 7.6. Hemophilia Market Attractiveness Analysis, By Replacement therapy 8. Global Hemophilia Market Analysis and Forecast, By Treatment 8.1. Introduction and Definition 8.2. Key Findings 8.3. Hemophilia Market Value Share Analysis, By Treatment 8.4. Hemophilia Market Size (US$ Bn) Forecast, By Treatment 8.5. Hemophilia Market Analysis, By Treatment 8.6. Hemophilia Market Attractiveness Analysis, By Treatment 9. Global Hemophilia Market Analysis and Forecast, By Type 9.1. Introduction and Definition 9.2. Key Findings 9.3. Hemophilia Market Value Share Analysis, By Type 9.4. Hemophilia Market Size (US$ Bn) Forecast, By Type 9.5. Hemophilia Market Analysis, By Type 9.6. Hemophilia Market Attractiveness Analysis, By Type 10. Global Hemophilia Market Analysis, by Region 10.1. Hemophilia Market Value Share Analysis, by Region 10.2. Hemophilia Market Size (US$ Bn) Forecast, by Region 10.3. Hemophilia Market Attractiveness Analysis, by Region 11. North America Hemophilia Market Analysis 11.1. Key Findings 11.2. North America Hemophilia Market Overview 11.3. North America Hemophilia Market Value Share Analysis, By Replacement therapy 11.4. North America Hemophilia Market Forecast, By Replacement therapy 11.4.1. ITI therapy 11.4.2. Gene therapy 11.5. North America Hemophilia Market Value Share Analysis, By Treatment 11.6. North America Hemophilia Market Forecast, By Treatment 11.6.1.1. On-demand 11.6.1.2. Prophylaxis 11.7. North America Hemophilia Market Value Share Analysis, By Type 11.8. North America Hemophilia Market Forecast, By Type 11.8.1. Hemophilia-A 11.8.2. Hemophilia-B 11.8.3. Hemophilia-C 11.8.4. Others 11.9. North America Hemophilia Market Value Share Analysis, by Country 11.10. North America Hemophilia Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Hemophilia Market Analysis, by Country 11.12. U.S. Hemophilia Market Forecast, By Replacement therapy 11.12.1. ITI therapy 11.12.2. Gene therapy 11.13. U.S. Hemophilia Market Forecast, By Treatment 11.13.1. On-demand 11.13.2. Prophylaxis 11.14. U.S. Hemophilia Market Forecast, By Type 11.14.1. Hemophilia-A 11.14.2. Hemophilia-B 11.14.3. Hemophilia-C 11.14.4. Others 11.15. Canada Hemophilia Market Forecast, By Replacement therapy 11.15.1. ITI therapy 11.15.2. Gene therapy 11.16. Canada Hemophilia Market Forecast, By Treatment 11.16.1. On-demand 11.16.2. Prophylaxis 11.17. Canada Hemophilia Market Forecast, By Type 11.17.1. Hemophilia-A 11.17.2. Hemophilia-B 11.17.3. Hemophilia-C 11.17.4. Others 11.18. North America Hemophilia Market Attractiveness Analysis 11.18.1. By Replacement therapy 11.18.2. By Treatment 11.18.3. By Type 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Hemophilia Market Analysis 12.1. Key Findings 12.2. Europe Hemophilia Market Overview 12.3. Europe Hemophilia Market Value Share Analysis, By Replacement therapy 12.4. Europe Hemophilia Market Forecast, By Replacement therapy 12.4.1. ITI therapy 12.4.2. Gene therapy 12.5. Europe Hemophilia Market Value Share Analysis, By Treatment 12.6. Europe Hemophilia Market Forecast, By Treatment 12.6.1. On-demand 12.6.2. Prophylaxis 12.7. Europe Hemophilia Market Value Share Analysis, By Type 12.8. Europe Hemophilia Market Forecast, By Type 12.8.1. Hemophilia-A 12.8.2. Hemophilia-B 12.8.3. Hemophilia-C 12.8.4. Others 12.9. Europe Hemophilia Market Value Share Analysis, by Country 12.10. Europe Hemophilia Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Hemophilia Market Analysis, by Country 12.12. Germany Hemophilia Market Forecast, By Replacement therapy 12.12.1. ITI therapy 12.12.2. Gene therapy 12.13. Germany Hemophilia Market Forecast, By Treatment 12.13.1. On-demand 12.13.2. Prophylaxis 12.14. Germany Hemophilia Market Forecast, By Type 12.14.1. Hemophilia-A 12.14.2. Hemophilia-B 12.14.3. Hemophilia-C 12.14.4. Others 12.15. U.K. Hemophilia Market Forecast, By Replacement therapy 12.15.1. ITI therapy 12.15.2. Gene therapy 12.16. U.K. Hemophilia Market Forecast, By Treatment 12.16.1. On-demand 12.16.2. Prophylaxis 12.17. U.K. Hemophilia Market Forecast, By Type 12.17.1. Hemophilia-A 12.17.2. Hemophilia-B 12.17.3. Hemophilia-C 12.17.4. Others 12.18. France Hemophilia Market Forecast, By Replacement therapy 12.18.1. ITI therapy 12.18.2. Gene therapy 12.19. France Hemophilia Market Forecast, By Treatment 12.19.1. On-demand 12.19.2. Prophylaxis 12.20. France Hemophilia Market Forecast, By Type 12.20.1. Hemophilia-A 12.20.2. Hemophilia-B 12.20.3. Hemophilia-C 12.20.4. Others 12.21. Italy Hemophilia Market Forecast, By Replacement therapy 12.21.1. ITI therapy 12.21.2. Gene therapy 12.22. Italy Hemophilia Market Forecast, By Treatment 12.22.1. On-demand 12.22.2. Prophylaxis 12.23. Italy Hemophilia Market Forecast, By Type 12.23.1. Hemophilia-A 12.23.2. Hemophilia-B 12.23.3. Hemophilia-C 12.23.4. Others 12.24. Spain Hemophilia Market Forecast, By Replacement therapy 12.24.1. ITI therapy 12.24.2. Gene therapy 12.25. Spain Hemophilia Market Forecast, By Treatment 12.25.1. On-demand 12.25.2. Prophylaxis 12.26. Spain Hemophilia Market Forecast, By Type 12.26.1. Hemophilia-A 12.26.2. Hemophilia-B 12.26.3. Hemophilia-C 12.26.4. Others 12.27. Rest of Europe Hemophilia Market Forecast, By Replacement therapy 12.27.1. ITI therapy 12.27.2. Gene therapy 12.28. Rest of Europe Hemophilia Market Forecast, By Treatment 12.28.1. On-demand 12.28.2. Prophylaxis 12.29. Rest Of Europe Hemophilia Market Forecast, By Type 12.29.1. Hemophilia-A 12.29.2. Hemophilia-B 12.29.3. Hemophilia-C 12.29.4. Others 12.30. Europe Hemophilia Market Attractiveness Analysis 12.30.1. By Replacement therapy 12.30.2. By Treatment 12.30.3. By Type 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Hemophilia Market Analysis 13.1. Key Findings 13.2. Asia Pacific Hemophilia Market Overview 13.3. Asia Pacific Hemophilia Market Value Share Analysis, By Replacement therapy 13.4. Asia Pacific Hemophilia Market Forecast, By Replacement therapy 13.4.1. ITI therapy 13.4.2. Gene therapy 13.5. Asia Pacific Hemophilia Market Value Share Analysis, By Treatment 13.6. Asia Pacific Hemophilia Market Forecast, By Treatment 13.6.1. On-demand 13.6.2. Prophylaxis 13.7. Asia Pacific Hemophilia Market Value Share Analysis, By Type 13.8. Asia Pacific Hemophilia Market Forecast, By Type 13.8.1. Hemophilia-A 13.8.2. Hemophilia-B 13.8.3. Hemophilia-C 13.8.4. Others 13.9. Asia Pacific Hemophilia Market Value Share Analysis, by Country 13.10. Asia Pacific Hemophilia Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Hemophilia Market Analysis, by Country 13.12. China Hemophilia Market Forecast, By Replacement therapy 13.12.1. ITI therapy 13.12.2. Gene therapy 13.13. China Hemophilia Market Forecast, By Treatment 13.13.1. On-demand 13.13.2. Prophylaxis 13.14. China Hemophilia Market Forecast, By Type 13.14.1. Hemophilia-A 13.14.2. Hemophilia-B 13.14.3. Hemophilia-C 13.14.4. Others 13.15. India Hemophilia Market Forecast, By Replacement therapy 13.15.1. ITI therapy 13.15.2. Gene therapy 13.16. India Hemophilia Market Forecast, By Treatment 13.16.1. On-demand 13.16.2. Prophylaxis 13.17. India Hemophilia Market Forecast, By Type 13.17.1. Hemophilia-A 13.17.2. Hemophilia-B 13.17.3. Hemophilia-C 13.17.4. Others 13.18. Japan Hemophilia Market Forecast, By Replacement therapy 13.18.1. ITI therapy 13.18.2. Gene therapy 13.19. Japan Hemophilia Market Forecast, By Treatment 13.19.1. On-demand 13.19.2. Prophylaxis 13.20. Japan Hemophilia Market Forecast, By Type 13.20.1. Hemophilia-A 13.20.2. Hemophilia-B 13.20.3. Hemophilia-C 13.20.4. Others 13.21. ASEAN Hemophilia Market Forecast, By Replacement therapy 13.21.1. ITI therapy 13.21.2. Gene therapy 13.22. ASEAN Hemophilia Market Forecast, By Treatment 13.22.1. On-demand 13.22.2. Prophylaxis 13.23. ASEAN Hemophilia Market Forecast, By Type 13.23.1. Hemophilia-A 13.23.2. Hemophilia-B 13.23.3. Hemophilia-C 13.23.4. Others 13.24. Rest of Asia Pacific Hemophilia Market Forecast, By Replacement therapy 13.24.1. ITI therapy 13.24.2. Gene therapy 13.25. Rest of Asia Pacific Hemophilia Market Forecast, By Treatment 13.25.1. On-demand 13.25.2. Prophylaxis 13.26. Rest of Asia Pacific Hemophilia Market Forecast, By Type 13.26.1. Hemophilia-A 13.26.2. Hemophilia-B 13.26.3. Hemophilia-C 13.26.4. Others 13.27. Asia Pacific Hemophilia Market Attractiveness Analysis 13.27.1. By Replacement therapy 13.27.2. By Treatment 13.27.3. By Type 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Hemophilia Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Hemophilia Market Overview 14.3. Middle East & Africa Hemophilia Market Value Share Analysis, By Replacement therapy 14.4. Middle East & Africa Hemophilia Market Forecast, By Replacement therapy 14.4.1. ITI therapy 14.4.2. Gene therapy 14.5. Middle East & Africa Hemophilia Market Value Share Analysis, By Treatment 14.6. Middle East & Africa Hemophilia Market Forecast, By Treatment 14.6.1. On-demand 14.6.2. Prophylaxis 14.7. Middle East & Africa Hemophilia Market Value Share Analysis, By Type 14.8. Middle East & Africa Hemophilia Market Forecast, By Type 14.8.1. Hemophilia-A 14.8.2. Hemophilia-B 14.8.3. Hemophilia-C 14.8.4. Others 14.9. Middle East & Africa Hemophilia Market Value Share Analysis, by Country 14.10. Middle East & Africa Hemophilia Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Hemophilia Market Analysis, by Country 14.12. GCC Hemophilia Market Forecast, By Replacement therapy 14.12.1. ITI therapy 14.12.2. Gene therapy 14.13. GCC Hemophilia Market Forecast, By Treatment 14.13.1. On-demand 14.13.2. Prophylaxis 14.14. GCC Hemophilia Market Forecast, By Type 14.14.1. Hemophilia-A 14.14.2. Hemophilia-B 14.14.3. Hemophilia-C 14.14.4. Others 14.15. South Africa Hemophilia Market Forecast, By Replacement therapy 14.15.1. ITI therapy 14.15.2. Gene therapy 14.16. South Africa Hemophilia Market Forecast, By Treatment 14.16.1. On-demand 14.16.2. Prophylaxis 14.17. South Africa Hemophilia Market Forecast, By Type 14.17.1. Hemophilia-A 14.17.2. Hemophilia-B 14.17.3. Hemophilia-C 14.17.4. Others 14.18. Rest of Middle East & Africa Hemophilia Market Forecast, By Replacement therapy 14.18.1. ITI therapy 14.18.2. Gene therapy 14.19. Rest of Middle East & Africa Hemophilia Market Forecast, By Treatment 14.19.1. On-demand 14.19.2. Prophylaxis 14.20. Middle East & Africa Hemophilia Market Forecast, By Type 14.20.1. Hemophilia-A 14.20.2. Hemophilia-B 14.20.3. Hemophilia-C 14.20.4. Others 14.21. Middle East & Africa Hemophilia Market Attractiveness Analysis 14.21.1. By Replacement therapy 14.21.2. By Treatment 14.21.3. By Type 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Hemophilia Market Analysis 15.1. Key Findings 15.2. South America Hemophilia Market Overview 15.3. South America Hemophilia Market Value Share Analysis, By Replacement therapy 15.4. South America Hemophilia Market Forecast, By Replacement therapy 15.4.1. ITI therapy 15.4.2. Gene therapy 15.5. South America Hemophilia Market Value Share Analysis, By Treatment 15.6. South America Hemophilia Market Forecast, By Treatment 15.6.1. On-demand 15.6.2. Prophylaxis 15.7. South America Hemophilia Market Value Share Analysis, By Type 15.8. South America Hemophilia Market Forecast, By Type 15.8.1. Hemophilia-A 15.8.2. Hemophilia-B 15.8.3. Hemophilia-C 15.8.4. Others 15.9. South America Hemophilia Market Value Share Analysis, by Country 15.10. South America Hemophilia Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Hemophilia Market Analysis, by Country 15.12. Brazil Hemophilia Market Forecast, By Replacement therapy 15.12.1. ITI therapy 15.12.2. Gene therapy 15.13. Brazil Hemophilia Market Forecast, By Treatment 15.13.1. On-demand 15.13.2. Prophylaxis 15.14. Brazil Hemophilia Market Forecast, By Type 15.14.1. Hemophilia-A 15.14.2. Hemophilia-B 15.14.3. Hemophilia-C 15.14.4. Others 15.15. Mexico Hemophilia Market Forecast, By Replacement therapy 15.15.1. ITI therapy 15.15.2. Gene therapy 15.16. Mexico Hemophilia Market Forecast, By Treatment 15.16.1. On-demand 15.16.2. Prophylaxis 15.17. Mexico Hemophilia Market Forecast, By Type 15.17.1. Hemophilia-A 15.17.2. Hemophilia-B 15.17.3. Hemophilia-C 15.17.4. Others 15.18. Rest of South America Hemophilia Market Forecast, By Replacement therapy 15.18.1. ITI therapy 15.18.2. Gene therapy 15.19. Rest of South America Hemophilia Market Forecast, By Treatment 15.19.1. On-demand 15.19.2. Prophylaxis 15.20. Rest of South America Hemophilia Market Forecast, By Type 15.20.1. Hemophilia-A 15.20.2. Hemophilia-B 15.20.3. Hemophilia-C 15.20.4. Others 15.21. South America Hemophilia Market Attractiveness Analysis 15.21.1. By Replacement therapy 15.21.2. By Treatment 15.21.3. By Type 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward 16.2.3.3. Integration 16.3. Company Profiles: Key Players 16.3.1. F.Hoffmann-La Roche Ltd. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Octapharma 16.3.3. CSL Behring 16.3.4. Kedrion 16.3.5. Sanofi 16.3.6. Bayer AG 16.3.7. Baxter 16.3.8. Swedish Orphan Biovitrum AB 16.3.9. Grifols International S.A 16.3.10. Shire 16.3.11. Pfizer Inc 16.3.12. Novo Nordisk A/S 16.3.13. Chugai Pharmaceutical Co.(Roche ) 16.3.14. BioMarin Pharmaceutical, Inc 17. Primary Key Insights

About This Report

Report ID67045
Category Healthcare
Published DateJuly 2020
No of Pages180
Contact Us
Call Now